Table 3 Symptoms in patients on somatostatin analogue treatment for metastatic disease from small-intestinal neuroendocrine tumour. EORTC GI.NET-21, values expressed as mean (standard deviation) Higher scores (1–100) indicate more severe symptoms
| Â | Baseline | 1-year follow-up |
|---|---|---|
Endocrine symptoms | 15.6 (17.5) | 13.0 (15.7) |
Gastrointestinal symptoms | 21.2 (15.6) | 18.7 (15.5) |
Treatment-related symptoms | 12.0 (14.1) | 10.2 (12.1) |
Social functioning | 27.8 (19.5) | 25.4 (17.7) |
Disease-related worries | 34.2 (21.5) | 30.1 (21.9) |
Muscle/bone pain | 31.4 (32.9) | 25.5 (29.1) |
Sexual functioning | 29.2 (36.4) | 28.6 (37.8) |
Information/communication | 6.1 (18.6) | 5.6 (14.7) |
Body image | 16.7 (28.6) | 13.9 (24.4) |